Toviaz Approved For Overactive Bladder

摘要

FDA on October 31 announced the U.S. marketing approval of fe-soterodine fumarate for the treatment of overactive bladder in adults.rnFesoterodine, which Pfizer will market as Toviaz, is described in its FDA-approved labeling as a competitive muscarinic-receptor antagonist that relaxes smooth muscles in the bladder. This action is believed to result in a reduction in urinary frequency, leakage, and the urge to urinate.rnFDA described as "statistically significant and clinically meaningful" the reduction in urinary frequency and incontinent episodes in patients who received fesoterodine instead of a placebo during clinical trials.